Protalix BioTherapeutics Inc. Q1 2023 Earnings Call

MLA.

You know by the end of the day, we hope to have a differentiation in the at least on the.

And improve the profile and at least in one important aspect.

Hey, Jim.

We will have to see if it would be the frequency of dosing the immunogenicity or a combination.

Great. Okay. That's helpful and last one for me just obviously next week is a huge week.

And what are the next steps that we should expect to see I know you mentioned that youre going to have a call with investors in another month.

<unk> priorities and things like that but what are the next steps, we should expect to see I guess from <unk> in terms of.

Commercialization and getting things ready, assuming we are getting a positive probably does that.

Sooner, we will clearly update immediately the market wants to see hopefully of course, we get the approval from the EU and followings out with the FDA. This is a sequence we see right now of course.

<unk>.

So we will of course update and explain them.

Not familiar with everything goes right no one's crazy he has he will plan.

The launch of the product that we will update.

<unk>.

Great Alright. Thank you Dror. Thank you al I appreciate your responses to my question.

Thank you John .

As a reminder, via the phone lines you May press. The one followed by the four if you'd like to register a question or comment once again that is the one followed by the four.

Okay.

Yes.

We show no further questions at this time I'll turn the call back over to our speakers for any closing remarks.

All of us to say, thank you everybody for your time.

We are looking forward of course to update you very very soon thank you very much.

Thank you. This does conclude the conference call for today, we thank you for your participation and ask that you. Please disconnect. Your lines. Thank you and have a good day.

Okay.

Correct.

[music].

Sure.